Apremilast: Could it be a Promising Solution for Difficult to Distinguish Cases of Palmo-Plantar Psoriasis and Acral Eczema: A Case Report

Ghada Kassir and Marwa Akhdar*

Department of Dermatology, AL Rassoul Al Aazam Hospital, Lebanon Department of Dermatology, Nabih Berri Governmental University Hospital, Lebanon

^*Correspondance to: Marwa Akhdar; gada Kassir 

 PDF  Full Text Case Report | Open Access

Abstract:

Hand eczema (HE) and palmar psoriasis (PP) are two chief complaints that cause severe functional and social impairment and have a detrimental effect on a patient's quality of life. These two types of dermatitis are close differential diagnoses where the clinical features of HE slightly differs from that of PP. Thus, distinguishing between the diagnoses stated above remains difficult because of the tremendous clinical overlap and similar histopathologic features between the two conditions, and also their similar clinical responses to the systemic treatment. Apremilast is a phosphodiesterase 4 (PDE4) inhibitor that has been approved for the treatment of moderate to severe psoriasis and atopic dermatitis. Given that apremilast impacts the pathology of both psoriasis and eczema, it presents itself as a practical treatment for the aforementioned cases when we are unsure of the diagnosis because of the similarity of the clinical aspects, inconclusive histopathologic reports, and cases of overlaps like "eczema in psoriatico".

Keywords:

Palmo-Plantar Psoriasis; Atopic dermatitis; Atopic eczema; Atopy; Apremilast

Cite the Article:

Kassir G, Akhdar M. Apremilast: Could it be a Promising Solution for Difficult to Distinguish Cases of Palmo-Plantar Psoriasis and Acral Eczema: A Case Report. Ann Clin Case Rep. 2025; 10: 2738..